Related Experiment Video
Updated: Aug 14, 2025
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage
Tiziana Scarnà1, Marion Menozzi-Arnaud1, Martin Friede2
1Gavi, the Vaccine Alliance, Geneva, Switzerland.
Introduction:
There is a need for investment in manufacturing for vaccine microarray patches (vMAPs) to accelerate vMAP development and access. vMAPs could transform vaccines deployment and reach to everyone, everywhere.
Areas Covered:
We outline vMAPs' potential benefits for epidemic preparedness and for outreach in low- and lower-middle-income countries (LMICs), share lessons learned from pandemic response, and highlight that investment in manufacturing-at-risk could accelerate vMAP development.
Expert Opinion:
Pilot manufacturing capabilities are needed to produce clinical trial material and enable emergency response. Funding vMAP manufacturing scale-up in parallel to clinical proof-of-concept studies could accelerate vMAP approval and availability. Incentives could mitigate the risks of establishing multi-vMAP manufacturing facilities early.
